Its growing pipeline of highly specific monoclonal antibodies is designed to treat a range of acute and chronic conditions that involve inflammatory, metabolic and fibrotic processes.

By combining new scientific insights with robust development expertise, the Belgium-based company claims to be building a company to lead to the emergence of truly regenerative medicines.